NPHC's Pompe budget is well-established at SAR 100-160M, but a new agent must clear a switch-approval rate of only 40-60% and price against a SAR 2.0-2.5M target already implied by avalglucosidase.
NPHC's Pompe enzyme replacement therapy programme covers both infantile- and late-onset disease under an annual budget estimated at SAR 100 to 160 million across 80 to 120 patients, averaging SAR 1 to 1.5 million per patient per year. Alglucosidase alfa (Lumizyme), the dominant formulary-covered ERT, costs SAR 800,000 to 1.2 million a year depending on patient weight at the standard biweekly dose. Avalglucosidase alfa (Nexviazyme), SFDA-registered since 2022, prices at a premium of SAR 1.2 to 1.8 million a year, but NPHC has not established routine switch criteria for existing alglucosidase patients; Sanofi is instead pursuing NPHC first-line approval to bypass the switch requirement for new patients entirely.
For a patient already on alglucosidase, individual case submission to switch requires 12 or more months of documented therapy, FVC decline of 5 percent or more (or a 6MWT decline of 10 percent or more), CRIM-status antibody assessment, and specialist endorsement, and clears at an estimated approval rate of only 40 to 60 percent. Beyond the drug cost itself, biweekly infusion logistics run SAR 30,000 to 60,000 per patient a year, a cost NPHC tracks closely and a lever KFSH&RC's home-infusion pilot already addresses. A new entrant without Sanofi's first-line pathway option should price at parity with avalglucosidase's forming SAR 1.2 to 1.8 million band, targeting SAR 2.0 to 2.5 million a year only if it can justify a premium through demonstrated ADA superiority or a materially lower infusion-logistics burden.
GCC Pompe pricing — NPHC-covered agents and the new-entrant target price
| Agent | GCC Registration / NPHC Status | Annual Cost (SAR) | Key Access Barrier |
|---|---|---|---|
| Alglucosidase alfa (Lumizyme) | SFDA registered; NPHC formulary-covered | 800,000-1,200,000 | Dominant ERT; 12-month continuation review required |
| Avalglucosidase alfa (Nexviazyme) | SFDA registered 2022; NPHC evaluation ongoing | 1,200,000-1,800,000 | Switch approval only 40-60%; Sanofi pursuing NPHC first-line bypass |
| New-entrant target (illustrative) | Hypothetical, not yet registered | 2,000,000-2,500,000 | Requires ADA-superiority or logistics-cost justification for premium |
Sources: NPHC Pompe disease programme guidelines 2023; GCC metabolic network registry; NPHC Pompe programme committee review process 2023; KFSH&RC home infusion pilot data 2022; Sanofi GCC rare disease team documentation.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NPHC's individual-case switch-submission criteria
- the CRIM-status and documented-decline requirements
- what evidence profile improves approval odds
Delivers
- NPHC's per-patient budget mechanics
- the alglucosidase-versus-avalglucosidase price gap
- the SAR 2.0-2.5M new-entrant target and what justifies a premium above it
Delivers
- The SAR 30-60K per-patient logistics cost
- KFSH&RC's home-infusion pilot
- the budget-efficiency argument for a home-infusion-enabled entrant
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the 40-60% NPHC switch-approval rate, not the WAC gap itself, is the binding constraint a new agent must clear
- Pressure-tested against the alglucosidase-vs-avalglucosidase precedent before the rest of the model is built out
- NPHC's SAR 100-160M annual Pompe ERT budget across 80-120 patients
- Where SAR 0.8-1.8M per-patient pricing already sits for alglucosidase and avalglucosidase
- The 12-month documented-decline and CRIM-status requirements gating a switch approval
- Why the approval rate clears at only 40-60%
- The SAR 0.8-1.2M vs 1.2-1.8M price gap and what it implies for a new entrant
- Sanofi's first-line approval strategy as a bypass to the switch requirement
- The SAR 30-60K per-patient logistics cost, separate from drug cost
- KFSH&RC's home-infusion pilot as a budget-efficiency argument
- The WAC, tender discount, and logistics components decomposed line by line
- The discount depth already observed in NPHC's existing formulary pricing
- Sequencing recommendation across KSA, UAE, Qatar, Kuwait, Oman, and Bahrain
- Conservative, base, and aggressive revenue scenarios tied to NPHC first-line approval timing
- The open pricing questions your team must close before the GCC launch price is locked
- Structured for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary regulatory sources (SFDA, NPHC) and live registration-tracking documentation, not secondary summaries. Findings are independently verified before inclusion.
Pompe GCC pricing sources: NPHC Pompe disease programme guidelines 2023, the GCC metabolic network registry, NPHC Pompe programme committee review process documentation, KFSH&RC home infusion pilot data 2022, and Sanofi GCC rare disease team documentation.
- NPHC annual Pompe ERT budget and per-patient cost verified against NPHC Pompe disease programme guidelines 2023
- Switch-approval rate and CRIM-status requirements verified against NPHC Pompe programme committee review process documentation
- Infusion logistics cost verified against KFSH&RC home infusion pilot data 2022
Frequently asked questions
Commission this model
AXLRx delivers Pompe disease pricing strategy models built for market access and pricing teams navigating NPHC's switch-approval mechanics and GCC tender dynamics. Custom model in 72 hours.
Specify your indication, market basket, and comparator scope.
AXLRx analyst confirms pricing mechanism assumptions and WTP threshold before building.
Research-verified pricing model in 72 hours with optional analyst readout.